[{"address1": "170 Harbor Way", "address2": "Suite 300", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 550 3500", "fax": "650 871 8580", "website": "https://vaxart.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.", "fullTimeEmployees": 105, "companyOfficers": [{"maxAge": 1, "name": "Mr. Steven  Lo", "age": 57, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 879327, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sean N. Tucker Ph.D.", "age": 56, "title": "Senior VP & Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 622439, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James F. Cummings M.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 679943, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeroen  Grasman M.B.A.", "title": "CFO, Principal Accounting Officer & Principal Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raymond D. Stapleton Jr., Ph.D.", "age": 52, "title": "Chief Technology Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edward B. Berg", "age": 59, "title": "Senior VP & General Counsel", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Laurie  Hastings", "title": "Senior Vice President of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shaily Jaini Garg", "title": "Senior Vice President of Clinical Development & Project Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rajesh  Kapoor Ph.D.", "title": "Senior Vice President of Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 6, "overallRisk": 9, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://newsroom.biotapharma.com/", "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.36, "open": 0.36, "dayLow": 0.3501, "dayHigh": 0.38, "regularMarketPreviousClose": 0.36, "regularMarketOpen": 0.36, "regularMarketDayLow": 0.3501, "regularMarketDayHigh": 0.38, "exDividendDate": 1352419200, "payoutRatio": 0.0, "beta": 1.13, "forwardPE": -0.87804884, "volume": 216708, "regularMarketVolume": 216708, "averageVolume": 4741441, "averageVolume10days": 525790, "averageDailyVolume10Day": 525790, "bid": 0.365, "ask": 0.37, "bidSize": 16506, "askSize": 6620, "marketCap": 82409040, "fiftyTwoWeekLow": 0.26, "fiftyTwoWeekHigh": 1.07, "priceToSalesTrailing12Months": 1.0208741, "fiftyDayAverage": 0.4352, "twoHundredDayAverage": 0.53775, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 76533376, "profitMargins": -0.70167, "floatShares": 226909155, "sharesOutstanding": 228914000, "sharesShort": 21173323, "sharesShortPriorMonth": 14348733, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.0928, "heldPercentInsiders": 0.00912, "heldPercentInstitutions": 0.1004, "shortRatio": 2.61, "shortPercentOfFloat": 0.094, "impliedSharesOutstanding": 228914000, "bookValue": 0.144, "priceToBook": 2.5000002, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -56642000, "trailingEps": -0.23, "forwardEps": -0.41, "lastSplitFactor": "1:11", "lastSplitDate": 1518566400, "enterpriseToRevenue": 0.948, "enterpriseToEbitda": -1.642, "52WeekChange": -0.60638297, "SandP52WeekChange": 0.15005577, "lastDividendValue": 12.188, "lastDividendDate": 1352419200, "quoteType": "EQUITY", "currentPrice": 0.36, "targetHighPrice": 4.0, "targetLowPrice": 2.0, "targetMeanPrice": 3.33333, "targetMedianPrice": 4.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 26271000, "totalCashPerShare": 0.115, "ebitda": -46601000, "totalDebt": 19020000, "quickRatio": 0.571, "currentRatio": 0.597, "totalRevenue": 80724000, "debtToEquity": 57.85, "revenuePerShare": 0.354, "returnOnAssets": -0.24972, "returnOnEquity": -1.00347, "grossProfits": -37475000, "freeCashflow": 47879376, "operatingCashflow": -37090000, "revenueGrowth": 5.207, "grossMargins": -0.46423998, "ebitdaMargins": -0.57729, "operatingMargins": -0.36756, "financialCurrency": "USD", "symbol": "VXRT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 4741441, "fiftyTwoWeekLowChange": 0.100000024, "fiftyTwoWeekLowChangePercent": 0.38461548, "fiftyTwoWeekRange": "0.26 - 1.07", "fiftyTwoWeekHighChange": -0.71000004, "fiftyTwoWeekHighChangePercent": -0.6635514, "fiftyTwoWeekChangePercent": -60.638298, "dividendDate": 1518566400, "earningsTimestamp": 1755115200, "earningsTimestampStart": 1762977600, "earningsTimestampEnd": 1762977600, "earningsCallTimestampStart": 1755117000, "earningsCallTimestampEnd": 1755117000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.23, "epsForward": -0.41, "epsCurrentYear": -0.29, "priceEpsCurrentYear": -1.2413794, "fiftyDayAverageChange": -0.07519999, "fiftyDayAverageChangePercent": -0.17279409, "twoHundredDayAverageChange": -0.17774999, "twoHundredDayAverageChangePercent": -0.3305439, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 376929000000, "corporateActions": [], "regularMarketTime": 1755287994, "exchange": "NCM", "messageBoardId": "finmb_37819645", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.36, "regularMarketChange": 0.0, "regularMarketDayRange": "0.3501 - 0.38", "shortName": "Vaxart, Inc. - Common Stock", "longName": "Vaxart, Inc.", "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "displayName": "Vaxart", "trailingPegRatio": null, "__fetch_time": "2025-08-16"}]